Market Closed -
Nasdaq
01:30:00 16/05/2024 am IST
5-day change
1st Jan Change
1.94
USD
+1.04%
+9.60%
+26.80%
This article is reserved for members
Not a member ?
Free registration
Transcript : Lexicon Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 08:00 AM
14/05
Lexicon Pharmaceuticals Says Post Hoc Analysis of Infepa Trial Showed Decreased Heart Failure Risk; Shares Gain Pre-Bell
14/05
MT
Lexicon Pharmaceuticals, Inc. Announces A New Post-Hoc Analysis of Clinical Data Showing That Inpefa® (Sotagliflozin), A Dual Oral Inhibitor of Sglt2 and Sglt1, Reduced the Risk of Heart Failure-Related Events Across A Diverse Population of Patients, Including Patients with Preserved Ejection Fraction
14/05
CI
Transcript : Lexicon Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 02, 2024
03/05
Earnings Flash (LXRX) LEXICON PHARMACEUTICALS Posts Q1 Revenue $1.1M, vs. Street Est of $1.4M
03/05
MT
Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
03/05
CI
Leerink Partners Starts Lexicon Pharmaceuticals With Outperform Rating, $5 Price Target
30/04
MT
Lexicon Pharmaceuticals' Chief Executive Lonnel Coats to Retire
29/04
MT
Lexicon Pharmaceuticals, Inc. Announces Resignation of Lonnel Coats as Member of Its Board of Directors, Effective July 7, 2024
29/04
CI
Lexicon Pharmaceuticals, Inc. Announces Resignation of Lonnel Coats as Chief Executive Officer, Effective from July 7, 2024
29/04
CI
Transcript : Lexicon Pharmaceuticals, Inc. - Analyst/Investor Day
22/04
Lexicon Pharmaceuticals Files Prospectus for Secondary Offering
26/03
MT
Lexicon Pharmaceuticals Shares Decline After Analysis Finds Similar Effect of Sotagliflozin in Type 1 Diabatic Patients
13/03
MT
Lexicon Pharmaceuticals, Inc. Announces New Post Hoc Analysis of Intandem3 Study Demonstrates Improvements in Glycemic Control with Sotagliflozin Treatment in Patients with Type 1 Diabetes and Chronic Kidney Disease
12/03
CI
Health Care Dips Amid Regulatory Doubts -- Health Care Roundup
12/03
DJ
Sector Update: Health Care Stocks Softer Late Afternoon
12/03
MT
Sector Update: Health Care Stocks Decline in Afternoon Trading
11/03
MT
Lexicon Pharmaceuticals Q4 Net Loss Widens, Revenue Rises; to Resubmit NDA for Sotagliflozin; Shares Jump
11/03
MT
Lexicon Pharmaceuticals Q4 Net Loss Widens, Revenue Rises; to Resubmit NDA for Sotagliflozin; Shares Gain Pre-Bell
11/03
MT
Lexicon Pharmaceuticals Shares Rise on Beat to 4Q Loss, Plans for Sotagliflozin
11/03
DJ
Earnings Flash (LXRX) LEXICON PHARMACEUTICALS Reports Q4 Revenue $702,000
11/03
MT
Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
11/03
CI
Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
11/03
CI
Lexicon Pharmaceuticals, Inc Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA
11/03
CI
Lexicon Pharmaceuticals, Inc. announced that it expects to receive $249.99995 million in funding
11/03
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The Company pipeline includes INPEFA (sotagliflozin), LX9211, and LX9851. Sotagliflozin is an orally delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. The Company is conducting preclinical development of LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and tool for weight management.
More about the company
Last Close Price
1.94
USD
Average target price
5.25
USD
Spread / Average Target
+170.62%
Consensus
1st Jan change
Capi.
+26.80% 70Cr +7.52% 11TCr +11.38% 11TCr -12.64% 2.22TCr +0.44% 2.23TCr -4.18% 1.94TCr -37.85% 1.79TCr -8.58% 1.72TCr +37.41% 1.25TCr -23.95% 834.13Cr
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**
-40% Limited Time Offer : Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff**
BENEFIT NOW **0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions**
#252525**/registration/member/**Blanc**1**7**To continue browsing, please register!**#ffffff50**14px**#33d251**